Skip to Main content Skip to Navigation
Master Thesis

Le syndrome des ovaires polykystiques : prise en charge à l'officine et place/intérêt du myo-inositol

Abstract : Affecting 5 to 10% of women of childbearing age, polycystic ovarian syndrome (PCOS) is the first cause of women infertility. It is characterised by three clinical criteria, whose association is neither constant nor mandatory : clinic and/or biologic hyperandrogenism, chronic dysovulation and presence of polycystic ovaries on ultrasound. Other metabolic disorders often occur such as android obesity and/or insulin-resistance which manifests itself by hyperinsulinism. Therefore, therapeutic strategy is not only focused on the syndrome gynecological side but is a part of a global pattern that takes into account the hormonal, metabolic and vasculary components. PCOS treatment is yet well-codified and associates drug therapy and lifestyle advice. Nevertheless, a better understanding of PCOS is necessary, in order to develop new therapeutic options and to optimize the medical care of PCOS women. Among these options, Myo-inositol aroused interest and seems to be promising although a standardisation of studies is necessary. Involved in insulin-resistance, its administration could decrease hyper-insulinism and improve hyperandrogenic and ovulation disorders. Used with fertility drugs, it could improve ovulation and pregnancy rates while preventing multiple pregnancies risk.
Document type :
Master Thesis
Complete list of metadatas

Cited literature [271 references]  Display  Hide  Download
Contributor : Santé Rennes 1 <>
Submitted on : Monday, June 11, 2018 - 10:18:00 AM
Last modification on : Thursday, July 9, 2020 - 12:30:44 PM


Files produced by the author(s)


  • HAL Id : dumas-01812002, version 1



Alizée Boinet. Le syndrome des ovaires polykystiques : prise en charge à l'officine et place/intérêt du myo-inositol. Sciences du Vivant [q-bio]. 2017. ⟨dumas-01812002⟩



Record views


Files downloads